Detection of Egfr Mutations with Mutation-Specific Antibodies in Primary Lesions of Non-Small Cell Lung Cancer

X. Zhang,L. Yin,X. Yang,J. Yang,Q. Zhou,J. Xu,Z. Xie,S. An,S. Chen,R. Wang,G. Zhu,Y. Gu,Y. L. Wu
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.7035
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:7035 Background: Patients with specific mutations in EGFR likely receive more benefit from EGFR TKI therapy. Here we evaluated the utility of EGFR mutation-specific antibodies in primary tumors for screening of EGFR-mutant NSCLC patients in comparison with a sequencing method. Methods: Immunohistochemistry (IHC) were performed on formalin-fixed, paraffin-embedded samples from primary lesions of 103 NSCLC patients, using antibodies against to wild-type EGFR, dEGFR (E746-A750 del) and L858R EGFR on the serial sections. Tumors with IHC scores of 1+ to 3+ scores were interpreted as IHC positive, and tumors with 0 score were considered as negative. Each of these samples was also subjected to direct sequencing for EGFR mutation status. Results: 27 of 103 cases were detected as EGFR E746-A750 del and L858R mutation by sequencing. Among the 13 EGFR E746-A750 del samples detected by sequencing, 11 of them were also scored IHC positive, with a sensitivity of 85% for the dEGFR antibody as compared with the direct sequencing method. In the rest of 90 cases which were negative for EGFR E746-A750 del by sequencing, the anti-dEGFR antibody detected 2 positive with a specificity of 98%. The anti-L858R EGFR antibody detected 9 positive out of 14 L858R mutation cases by sequencing, with a sensitivity of 64%. In the other 89 cases which were negative for L858R mutation by sequencing, the anti-L858R EGFR antibody detected 5 positive with a specificity of 94%. In combination of the results from both antibodies, the overall sensitivity of the IHC method was 74% (20/27), and the specificity was 92% (70/76) as compared with the direct sequencing method. In addition, sequencing showed several EGFR mutations other than dEGFR or L858R in 12 cases. None of these 12 cases were detected positive by using the two IHC antibodies. Conclusions: Given over 90% specificity, our results suggested IHC using the two mutation specific antibodies could be an ancillary method for EGFR mutation screening in the NSCLC patients, especially when there is not enough tumor tissues for sequencing detection. The utility of the IHC method with mutation-specific antibodies would need further validation in clinical studies.
What problem does this paper attempt to address?